title: Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.
authors.forename: Vanessa
authors.initials: V
authors.lastname: Sivam
authors.forename: Lucy
authors.initials: L
authors.lastname: Cook
authors.forename: George
authors.initials: G
authors.lastname: Hughes
authors.forename: Anasatasios
authors.initials: A
authors.lastname: Karadimitris
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: Marks
authors.forename: Francis
authors.initials: F
authors.lastname: Matthey
authors.forename: Kikkeri N
authors.initials: KN
authors.lastname: Naresh
authors.forename: Richard M
authors.initials: RM
authors.lastname: Szydlo
authors.forename: Helen
authors.initials: H
authors.lastname: Yarranton
authors.forename: Edward J
authors.initials: EJ
authors.lastname: Kanfer
authors.forename: Donald H
authors.initials: DH
authors.lastname: Macdonald
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine; D055815:Young Adult; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine